Activating anti-CD40 antibodies induce tumour invasion by cytotoxic T-lymphocytes and inhibition of tumour growth in experimental liver cancer

European Journal of Cancer

Volumn 42, Issue 7, 2006, Pages 981-987

  Ryschich, Eduard ^a   Märten, Angela ^a   Schmidt, Eduard ^a   Linnebacher, Michael ^a   Wentzensen, Nicolas ^a   Eisold, Sven ^a   Klar, Ernst ^a   Büchler, Markus W ^a   Schmidt, Jan ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

CD40; Immunotherapy; Liver cancer; Microcirculation; Rat

Indexed keywords

ACTIVATING CD40 ANTIBODY; CD40 ANTIGEN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER INVASION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; IMMUNOHISTOLOGY; LEUKOCYTE ADHERENCE; LEUKOCYTE MIGRATION; MALE; MICROSCOPY; MORRIS HEPATOMA; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; RAT; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR VOLUME; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIBODIES; ANTIBODY FORMATION; ANTIGENS, CD40; CD4-POSITIVE T-LYMPHOCYTES; CELL ADHESION; CELL DIVISION; CELL LINE, TUMOR; IMMUNOTHERAPY; LIVER NEOPLASMS, EXPERIMENTAL; MALE; NEOPLASM TRANSPLANTATION; RATS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 33646176535     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.01.024     Document Type: Article

References (26)

1. Lin D.Y., Lin S.M., and Liaw Y.F. Non-surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 12 (1997) S319
2. Ohmoto K., Tsuduki M., Shibata N., et al. Percutaneous microwave coagulation therapy for hepatocellular carcinoma located on the surface of the liver. Am J Roentgenol 173 (1999) 1231
3. The Liver Cancer Study Group of Japan. Primary liver cancer in Japan: clinicopathologic features and results of surgical treatment. Ann Surg 211 (1990) 277-287
4. Grewal I.S., and Flavell R.A. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 16 (1998) 111-135
5. Costello R.T., Gastaut J.-A., and Olive D. What is the real role of CD40 in cancer immunotherapy?. Immunol Today 20 (1999) 488
6. Nakajama A., Kodama T., Morimoto S., et al. Antitumour effect of CD40 ligand: elicitation of local and systemic antitumour responses by IL-12 and B7. J Immunol 161 (1998) 1901
7. Mehal W.Z., Azzaroli F., and Crispe I.N. Immunology of the healthy liver: old questions and new insights. Gastroenterology 120 (2001) 250-260
8. Fleming K.A. The anatomy of the normal liver and the hepatic lymphocyte. In: Crispe I.N. (Ed). T lymphocytes in the liver; immunobiology, pathology and host defense (1999), Wiley-Liss, New York 1-15
9. Norris S., Collins C., Doherty D.G., et al. Resident human hepatic lymphocytes are phenotypically different from circulating lymphocytes. J Hepatol 28 (1998) 84-90
10. Maksan S.M., Paulo H., Ryschich E., et al. In vivo assessment of angioarchitecture and microcirculation in experimental liver cancer: a new model in rats. Dig Dis Sci 48 2 (2003) 279-290
11. Morris H.P., and Slaughter L.J. Historical development of transplantable hepatomas. In: Morris H.P., and Criss W.E. (Eds). Adv Exp Med Biol vol. 92 (1978), Plenum Press, New York, London 1-19
12. Baatz H., Steinbauer M., Harris A.G., et al. Kinetics of white blood cell staining by intravascular administration of rhodamine 6G. Int J Microcirc Clin Exp 15 (1995) 85-91
13. Schoenberger S.P., Toes R.E., van der Voort E.I., et al. T-cell help for cytotoxic T lymphocytes by CD40-CD40L interactions. Nature 393 (1998) 480-483
14. Ridge J.P., Di Rosa F., and Matzinger P.A. Aconditioned dendritic cell can be temporal bridge between a CD4+ T-helper and T-killer cell. Nature 393 (1998) 474-478
15. Panes J., and Granger D.N. Leukocyte-endothelial cell interactions: molecular mechanisms and implications in gastrointestinal disease. Gastroenterology 114 (1998) 1066-1099
16. Thienel U., Loike J., and Yellin M.J. CD154 (CD40L) induces human endothelial cell chemokine production and migration of leukocyte subsets. Cell Immunol 198 (1999) 87-95
17. Goldsmith H.L., and Spain S. Margination of leukocytes in blood flow through small tubes. Microvasc Res 27 (1984) 204-222
18. Schmidt J., Ryschich E., Volker D., et al. Vascular structure and microcirculation of experimental pancreatic carcinoma in rats. Eur J Surg 166 (2000) 1102-4151
19. Griffioen A.W., Damen C.A., Blijham G.H., et al. Tumour angiogenesis is accompanied by a decreased inflammatory response of tumour-associated endothelium. Blood 88 (1996) 667-673
20. French R.R., Chan H.T.C., Tutt A.L., et al. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med 5 (1999) 548-553
21. Baxevanis C.N., Voutsas I.F., Tsitsilonis O.E., et al. Tumour-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumour. J Immunol 164 (2000) 3902-3912
22. Turner J.G., Rakhmilevich A.L., Burdelya L., et al. Anti-CD40 antibody induces antitumour and antimetastatic effects: the role of NK cells. J Immunol 166 (2001) 89-94
23. Fernandez N.C., Lozier A., Flament C., et al. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumour immune responses in vivo. Nat Med 5 (1999) 405-411
24. Ockert D., Schmitz M., Hampl M., et al. Advances in cancer immunotherapy. Immunol Today 20 (1999) 63-65
25. Gruss H.J., Hirschstein D., Wright B., et al. Expression and function of CD40 on Hodgkin and Reed-Sternberg cells and the possible relevance for Hodgkin's disease. Blood 84 (1994) 2305-2314
26. Aggarwal B.B., and Natarajan K. Tumour necrosis factors: developments during the last decade. Eur Cytocine Netw 7 (1996) 93-124